← Eichor
Study identifier: NCT06654193 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Condition: Acute Kidney Injury  ·  Sponsor: Hope Biosciences LLC

PhasePhase 1/Phase 2
Planned participants70
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

This description comes directly from the study's public registry record.

Talk to the study team

Charles S Cox, Jr., MD  ·  713-500-7307  ·  Charles.S.Cox@uth.tmc.edu

Always discuss trial participation with your own doctor first.

Locations (3)

University of Alabama at BirminghamBirmingham, Alabama, United StatesNot Yet Recruiting
University of California, San FranciscoSan Francisco, California, United StatesNot Yet Recruiting
University of Texas Health Science Center at Houston (UTHealth Houston)Houston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06654193